Corton Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Corton Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,025	Closed	-$244K	–	623
2024 Q1	$244K	Buy	2,025 +88	+5%	+$10.8K	0.09%	346
2023 Q4	$238K	Buy	+1,937	New	+$242K	0.08%	406
2022 Q3	–	Sell	-1,440	Closed	-$225K	–	319
2022 Q2	$225K	Sell	1,440 -1,651	-53%	-$254K	0.21%	202
2022 Q1	$481K	Buy	+3,091	New	+$449K	0.21%	123

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Corton Capital's JAZZ Position: Q2 2024 in Review

Corton Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 2,025 shares — an estimated $244K sold.

Corton Capital first reported a position in JAZZ in Q1 2022 and held it in 4 quarters. The position peaked at $481K in Q1 2022. 456 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

Corton Capital reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Corton Capital sold 2,025 Jazz Pharmaceuticals shares in Q2 2024, an estimated $244K.
Corton Capital first reported a position in Jazz Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Corton Capital's Jazz Pharmaceuticals position peaked at $481K in Q1 2022.
456 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Corton Capital's 13F filing for Q2 2024, filed 14 Aug 2024.